Stockscreener 앱 받기
2.495
0.80%
-0.015
Kiora Pharmaceuticals Inc 주식(KPRX)의 최신 뉴스
Kiora Pharmaceuticals Inc expected to post a loss of 71 cents a shareEarnings Preview - TradingView
[ARS] KIORA PHARMACEUTICALS INC SEC Filing - Stock Titan
KPRX Kiora Pharmaceuticals reports far wider Q4 2025 loss than estimates, shares hold flat in today’s trading. - Newser
KPRX SEC FilingsKIORA PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Kiora Pharmaceuticals (NASDAQ: KPRX) details 2026 director, pay and equity plan votes - Stock Titan
KPHMW SEC FilingsKiora Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Kiora Pharmaceuticals (KPRX) Industry Outlook | Q4 2025: Earnings UnderperformRevision Downgrade - Cổng thông tin điện tử tỉnh Lào Cai
KPRX Kiora Pharmaceuticals posts far wider Q4 2025 loss than estimates, shares dip nearly 2 percent today.Cycle Outlook - Cổng thông tin điện tử tỉnh Tây Ninh
Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway - TMX Newsfile
A light-activated eye drug cleared Phase 1 safety and moved into Phase 2 - Stock Titan
Perceptive Fund (RLAY) reports 9.99% ownership — 438,471 shares - Stock Titan
Breakouts Watch: Is Kiora Pharmaceuticals Inc still a buy after recent gains2026 Action & Advanced Technical Signal Analysis - baoquankhu1.vn
Trend Recap: Will Kiora Pharmaceuticals Inc outperform its industry peers2026 Sentiment & Daily Profit Maximizing Tips - baoquankhu1.vn
What accelerates growth of Kiora Pharmaceuticals (KPRX) Stock | Price at $2.39, Down 3.24%Hot Momentum Watchlist - Newser
Profit Review: Is Kiora Pharmaceuticals Inc a cyclical or defensive stock2026 Breakouts & Breakdowns & Safe Capital Growth Plans - baoquankhu1.vn
KPRX Technical Analysis & ETF Price Forecast - Intellectia AI
Why Did KPRX Stock Surge 17% Pre-Market Today? - Stocktwits
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
KPRX Faces Tumultuous Trading: Strategic Moves Amid Market Fluctuations - timothysykes.com
Kiora Pharmaceuticals Surges 23.5% Intraday – What's Fueling the Rally? - Bitget
KiORa Pharmaceuticals (KPRX) Stock: Jumps 24% After $24M Private Placement Deal - parameter.io
Kiora Pharmaceuticals closes $24M private placement By Investing.com - Investing.com South Africa
Kiora Pharmaceuticals’ Stock Analysis amidst Financial Challenges - StocksToTrade
Kiora Pharmaceuticals Inc. Poised for Strategic Expansion Amid Market Challenges - timothysykes.com
According to the latest filings disclosed by the U.S. Securities and Exchange Commission (SEC), biopharmaceutical company Kiora Pharmaceuticals (stock code: KPRX) plans to privately place 438,471 shares of its common stock to specific investors. - Bitget
Kiora Pharmaceuticals Announces $5 Million Private Placement Financing - TipRanks
Kiora Pharmaceuticals IncEnters Securities Purchase Agreement On April 3, 2026SEC Filing - TradingView
Kiora Pharmaceuticals closes $24M private placement - Investing.com
Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors - TMX Newsfile
Two biotech investors back Kiora with $5M now, $19M more later - Stock Titan
Kiora Pharmaceuticals Raises $5 Million in Private Placement With $19 Million Warrant UpsideTradingView - TradingView - Alle Märkte im Blick
Kiora (NASDAQ: KPRX) secures up to $24M in milestone-based private placement - Stock Titan
Kiora Pharmaceuticals chief development officer to depart By Investing.com - Investing.com India
Critical Outcome Technologies (OTCMKTS:COTQF) and Kiora Pharmaceuticals (NASDAQ:KPRX) Head to Head Survey - Defense World
Kiora Pharmaceuticals Announces Chief Development Officer Resignation - TipRanks
Kiora Pharmaceuticals chief development officer to depart - Investing.com
Eric J. Daniels to Resign as Kiora Chief Development Officer Effective April 17, 2026 - TradingView
Kiora Pharmaceuticals (KPRX) CFO uses 929 shares to cover taxes - Stock Titan
Kiora (NASDAQ: KPRX) executive uses 929 shares to satisfy tax withholding - Stock Titan
Kiora (KPRX) CEO withholds 1,906 shares to cover stock taxes - Stock Titan
Kiora Pharmaceuticals (NASDAQ: KPRX) details CDO exit and trial progress - Stock Titan
Kiora says retinal disease trials keep enrolling after exec exit - Stock Titan
KPRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Will Kiora Pharmaceuticals Inc outperform its industry peersProduct Launch & Safe Entry Zone Identification - baoquankhu1.vn
Should I hold or sell Kiora Pharmaceuticals Inc nowQuarterly Market Review & Accurate Trade Setup Notifications - baoquankhu1.vn
Kiora Pharmaceuticals Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Kiora Pharmaceuticals reports $10.8M loss for 2025 By Investing.com - Investing.com Canada
Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials - Bitget
Kiora Pharmaceuticals reports $10.8M loss for 2025 - Investing.com
Kiora Pharmaceuticals posts 2025 net loss as expenses rise - TradingView
Kiora Pharmaceuticals 10-K: $0M Revenue, $(10.84)M Net Loss - TradingView
Kiora (NASDAQ: KPRX) posts 2025 loss while funding two active Phase 2 trials - Stock Titan
Retinal disease pipeline at Kiora Pharmaceuticals (NASDAQ: KPRX) - Stock Titan
If You Invested $1,000 in KIORA PHARMACEUTICALS INC (KPRX) - Stock Titan
0.78%
3.99%
자본화:
|
볼륨(24시간):